These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6443379)

  • 1. Effects of a dose increase on chronic opiate use during methadone detoxification.
    Stitzer ML; McCaul ME; Bigelow GE; Liebson IA
    NIDA Res Monogr; 1984; 55():197-201. PubMed ID: 6443379
    [No Abstract]   [Full Text] [Related]  

  • 2. Contingent methadone dose increases as a method for reducing illicit opiate use in detoxification patients.
    Higgins ST; Stitzer ML; Bigelow GE; Liebson IA
    NIDA Res Monogr; 1984; 55():178-84. PubMed ID: 6443376
    [No Abstract]   [Full Text] [Related]  

  • 3. Methadone detoxification: effects of methadone dose versus time in treatment.
    McCaul ME; Stitzer ML; Bigelow GE; Liebson IA
    NIDA Res Monogr; 1984 Mar; 49():269-74. PubMed ID: 6434971
    [No Abstract]   [Full Text] [Related]  

  • 4. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the dose on the severity of opiate withdrawal symptoms during methadone detoxification.
    Glasper A; Gossop M; de Wet C; Reed L; Bearn J
    Pharmacology; 2008; 81(2):92-6. PubMed ID: 17952010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outpatient methadone detoxification: effects of diazepam and doxepin as adjunct medications.
    McCaul ME; Stitzer ML; Bigelow GE; Liebson IA
    NIDA Res Monogr; 1984; 55():191-6. PubMed ID: 6443378
    [No Abstract]   [Full Text] [Related]  

  • 7. Methadone-induced bradycardia.
    Ashwath ML; Ajjan M; Culclasure T
    J Emerg Med; 2005 Jul; 29(1):73-5. PubMed ID: 15961013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a behavioral and a pharmacological treatment for reduction of illicit opiate use.
    Stitzer ML; McCaul ME; Bigelow GE; Liebson IA
    NIDA Res Monogr; 1984 Mar; 49():255-61. PubMed ID: 6434969
    [No Abstract]   [Full Text] [Related]  

  • 9. Opiate-dependent patients receiving methadone. How physicians should manage therapy.
    Kahan M; Sutton N
    Can Fam Physician; 1996 Sep; 42():1769-78. PubMed ID: 8828879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans.
    Donny EC; Walsh SL; Bigelow GE; Eissenberg T; Stitzer ML
    Psychopharmacology (Berl); 2002 May; 161(2):202-12. PubMed ID: 11981600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
    Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
    J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic opiate use during methadone detoxification: effects of a dose increase treatment.
    Stitzer ML; McCaul ME; Bigelow GE; Liebson IA
    Drug Alcohol Depend; 1984 Sep; 14(1):37-44. PubMed ID: 6489151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-regulated opioid detoxification by humans: effects of methadone pretreatment.
    McLeod DR; Bigelow GE; Liebson IA
    NIDA Res Monogr; 1982 Apr; 41():232-8. PubMed ID: 6811914
    [No Abstract]   [Full Text] [Related]  

  • 14. Lack of toxicity of high dose propoxyphene napsylate when used for maintenance treatment of addiction.
    Woody GE; Tennant FS; McLellan AT; O'Brien CP; Mintz J
    NIDA Res Monogr; 1979; 27():435-40. PubMed ID: 44894
    [No Abstract]   [Full Text] [Related]  

  • 15. Initial opiate use and treatment outcome in methadone detoxification patients.
    McCaul ME; Stitzer ML; Bigelow GE; Liebson IA
    NIDA Res Monogr; 1983 Apr; 43():280-6. PubMed ID: 6410262
    [No Abstract]   [Full Text] [Related]  

  • 16. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
    McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
    Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Buprenorphine or methadone for detoxification of young opioid addicts?].
    Ebner R; Schreiber W; Zierer C
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S108-10. PubMed ID: 15570521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rationale for naltrexone therapy as an alternative to methadone treatment for opiate addiction.
    Simon DL
    Conn Med; 1996 Nov; 60(11):683-5. PubMed ID: 8979434
    [No Abstract]   [Full Text] [Related]  

  • 19. Torsades de pointes with methadone.
    Prescrire Int; 2005 Apr; 14(76):61-2. PubMed ID: 15875343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prescribing methadone for the opiate addict: a problem of dosage conversion.
    Johns AR; Gossop M
    Drug Alcohol Depend; 1985 Sep; 16(1):61-6. PubMed ID: 4064909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.